House Investigation Of COX-2 Promotional Practices Turns Attention To Pfizer
This article was originally published in The Pink Sheet Daily
Executive Summary
Government Reform Committee members discuss extending their investigation on Vioxx promotional practices to other COX-2 drugs. FDA Office of New Drugs' Jenkins rebukes Merck for avoiding discussion of certain cardiovascular risk data during physician detailing visits before a 2002 Vioxx labeling change.
You may also be interested in...
Vioxx Detailing Practices Questioned In Independent Review
Report contracted by Merck finds company’s senior management acted with integrity relating to development, testing and marketing of the COX-2 inhibitor, however.
Vioxx Detailing Practices Questioned In Independent Review
Report contracted by Merck finds company’s senior management acted with integrity relating to development, testing and marketing of the COX-2 inhibitor, however.
Merck CEO Clark Brings Managed Care Expertise To Post; Gilmartin Retires
Richard Clark's appointment signals the importance Merck is placing on managed care ahead of the January 2006 start of the Medicare drug benefit. Merck also is highlighting Clark's manufacturing expertise, but acknowledges he will rely on Merck Research Labs President Peter Kim for advice on R&D strategy.